Tilray Medical Enhances German Cannabis Offerings with New Strains
Tilray Medical Expands Our Product Portfolio in Germany
Tilray Medical, a dedicated division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is making significant strides in the medicinal cannabis sector by launching new cannabis strains designed for patients in Germany. These new offerings include the Good Supply Cannabisblüten THC 22 IIM, THC 25 MMK, and THC 18 LLD. Each strain is certified under EU-GMP standards, ensuring high quality and safety for consumers.
Collaborative Care for Patients
Rajnish Ohri, the Managing Director, International at Tilray Brands, emphasized the company's commitment to enhancing patient care and global healthcare standards. He pointed out that the launch of these strains not only expands access to high-quality medical cannabis but also solidifies the company’s position as a trusted partner in the industry. By leveraging Tilray’s expansive distribution network and international reach, they aim to provide reliable access to safe and effective medical choices.
Details of New Cannabis Strains
The newly introduced strains will be released in different variants to cater to various patient needs. The Good Supply Cannabisblüten THC 22 IIM is set to be available starting from early September, while the THC 25 MMK is set for release on September 19, followed by THC 18 LLD by the end of September or early October. All strains will be offered in both 15 g jars for individual patients and larger 500 g packs for pharmacies, thus accommodating a wide spectrum of consumer requirements.
Quality Assurance and Supply Chain Integrity
Tilray Medical ensures that their medical cannabis products undergo rigorous quality control managed through EU-GMP certified facilities. This commitment ensures pharmacies throughout Germany receive consistent, high-quality products that are readily available for patients requiring medicinal cannabis. Tilray’s distribution capabilities in Germany are designed to support pharmacies and offer patients access to products that they can trust.
The Mission of Tilray Medical
Tilray Medical's vision is to transform lives through a safe and reliable access to top-notch medical cannabis brands. By focusing on patient needs, Tilray Medical continuously adjusts its product offerings. The company has established itself as a significant supplier of medical cannabis by providing a diverse portfolio that resonates with patients' varying requirements.
Our Global Impact
Having started as one of Canada’s first licensed producers of medical cannabis, Tilray has expanded its operations to include the establishment of EU-GMP certified production facilities in Portugal and Germany. The organization's growth trajectory reflects its dedication to addressing the needs of patients across the globe, providing an array of trusted products under various brands, including Good Supply and others, catering to medical use.
Frequently Asked Questions
What new strains has Tilray Medical launched for Germany?
Tilray Medical has launched three new cannabis strains: THC 22 IIM, THC 25 MMK, and THC 18 LLD, all certified under EU-GMP standards.
When will these new strains be available?
The THC 22 IIM strain will be available in early September, THC 25 MMK on September 19, and THC 18 LLD by the end of September or early October, in both 15 g and 500 g sizes.
How is Tilray Medical ensuring product quality?
Tilray Medical’s products are produced in EU-GMP certified facilities, ensuring high standards of quality and safety for patients and pharmacies.
What is Tilray Medical's mission?
Tilray Medical is committed to transforming lives by providing safe, reliable access to premium medical cannabis products while fostering a supportive healthcare environment.
What is the importance of the distribution network for Tilray?
Tilray's robust distribution network allows for consistent supply and quality assurance of medical cannabis products, ensuring they reach pharmacies and patients efficiently.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
